ReVision Implant closed an oversubscribed €4M round from private investors, including European business leaders and medtech operators alongside existing backers. The Belgian company is building Occular, a visual cortical prosthesis that bypasses the eye to stimulate the visual cortex directly, positioned for patients that retinal implants cannot reach. The raise follows FDA Breakthrough Device designation earlier this year and funds a move from preclinical work toward clinical and operational scale-up. A first short-term clinical test is scheduled for October 2026.